The manufacturing of Strangvac, a vaccine against the highly contagious equine disease strangles, takes place in two steps - first the antigens are produced in a process that yields sufficient antigens for several million doses, then vaccine doses are produced by mixing the antigens with adjuvant and saline. The reconstituted vaccine doses are transferred into vials that are labelled and packaged for sale. The antigens produced in step one can now be used for mixing with adjuvant and saline based upon the new extended shelf life of 28 months from the time of manufacture. The shelf life of the labelled vaccine doses in vials then has a further approved shelf life of 24 months, which is not limited by the shelf life of the antigens.
"This is excellent news as we move towards the launch of Strangvac. The approval of a 28-month shelf life for the antigens in Strangvac provides increased flexibility in the manufacturing process. The antigens in Strangvac are very stable and this approval was expected, but we are delighted that it is now in place" says Dr.
"Our plan for sales of Strangvac® to start in March remains unchanged." said
For more information please contact:
Phone: +46-8-120 10 601, cell +46-73-335 99 70
E-mail: andreas.andersson@intervacc.com
The information was submitted for publication, through the agency of the contact person set out above on
About
About equine strangles
Equine strangles, caused by Streptococcus equi, is the most frequently diagnosed infectious disease of horses, and affects horses all over the world with one exception
Contact information for Certified Adviser
E-mail: adviser@eminova.se, Phone: +46 (0)8 - 684 211 10
https://news.cision.com/intervacc/r/the-european-medicines-agency-extends-the-shelf-life-of-the-antigens-used-in-strangvac-to-28-months-,c3521631
https://mb.cision.com/Main/4632/3521631/1546201.pdf
https://news.cision.com/intervacc/i/lntervacc-,c3022056
(c) 2022 Cision. All rights reserved., source